APA (7th ed.) Citation

Bitzer, M., & Ganten, T. M. (2016). Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma: The SHELTER study. Journal of hepatology, 65(2), . https://doi.org/10.1016/j.jhep.2016.02.043

Chicago Style (17th ed.) Citation

Bitzer, Michael, and Tom M. Ganten. "Resminostat Plus Sorafenib as Second-line Therapy of Advanced Hepatocellular Carcinoma: The SHELTER Study." Journal of Hepatology 65, no. 2 (2016). https://doi.org/10.1016/j.jhep.2016.02.043.

MLA (9th ed.) Citation

Bitzer, Michael, and Tom M. Ganten. "Resminostat Plus Sorafenib as Second-line Therapy of Advanced Hepatocellular Carcinoma: The SHELTER Study." Journal of Hepatology, vol. 65, no. 2, 2016, https://doi.org/10.1016/j.jhep.2016.02.043.